Skip to main content

Table 2 Adverse events (all grades [≥10%] and grades 3/4, regardless of causality) by treatment group

From: A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

Preferred term, n (%)

3 mg/kg QW

n = 1

10 mg/kg QW

n = 5

20 mg/kg QW

n = 6

40 mg/kg QW

RDE, n = 36

20 mg/kg Q2W

n = 6

All patients N = 54

 

All grades

Grade 3/4

All grades

Grade 3/4

All grades

Grade 3/4

All grades

Grade 3/4

All grades

Grade 3/4

All grades

Grade 3/4

Diarrhea

0

0

2 (40)

0

5 (83)

1 (17)

18 (50)

1 (3)

3 (50)

1 (17)

28 (52)

3 (6)

Decreased appetite

0

0

3 (60)

0

4 (67)

0

16 (44)

0

1 (17)

0

24 (44)

0

Pyrexia

0

0

2 (40)

0

2 (33)

0

18 (50)

1 (3)

0

0

22 (41)

1 (2)

Fatigue

0

0

2 (40)

0

2 (33)

1 (17)

14 (39)

0

1 (17)

0

19 (35)

1 (2)

Nausea

1 (100)

0

3 (60)

0

3 (50)

1 (17)

12 (33)

1 (3)

0

0

19 (35)

2 (4)

Infusion-related reaction

0

0

0

0

3 (50)

0

13 (36)

0

1 (17)

0

17 (31)

0

Vomiting

1 (100)

0

1 (20)

0

2 (33)

1 (17)

10 (28)

2 (6)

2 (33)

0

16 (30)

3 (6)

Constipation

1 (100)

0

0

0

3 (50)

0

10 (28)

0

1 (17)

0

15 (28)

0

Dyspnea

0

0

1 (20)

0

1 (17)

1 (17)

10 (28)

2 (6)

3 (50)

1 (17)

15 (28)

4 (7)

Anemia

0

0

1 (20)

0

3 (50)

1 (17)

10 (28)

6 (17)

0

0

14 (26)

7 (13)

Hypomagnesemia

0

0

3 (60)

0

5 (50)

0

7 (19)

0

1 (17)

0

14 (26)

0

Hypokalemia

1 (100)

0

2 (40)

0

0

0

9 (25)

4 (11)

1 (17)

0

13 (24)

4 (7)

Chills

0

0

0

0

2 (33)

0

11 (31)

0

0

0

13 (24)

0

Cough

0

0

1 (20)

0

1 (17)

0

8 (22)

0

1 (17)

0

11 (20)

0

Headache

0

0

2 (40)

0

1 (17)

0

7 (19)

0

0

0

10 (19)

0

Stomatitis

0

0

0

0

2 (33)

0

7 (19)

0

1 (17)

0

10 (19)

0

AST increased

0

0

2 (40)

0

1 (17)

0

6 (17)

0

0

0

9 (17)

0

Asthenia

0

0

0

0

2 (33)

1 (17)

5 (14)

1 (3)

2 (33)

1 (17)

9 (17)

3 (6)

Myalgia

0

0

0

0

1 (17)

0

7 (19)

0

1 (17)

0

9 (17)

0

Blood ALP increased

1 (100)

0

1 (20)

0

2 (33)

0

4 (11)

2 (6)

0

0

8 (15)

2 (4)

Hypophosphatemia

0

0

0

0

0

0

8 (22)

5 (14)

0

0

8 (15)

5 (9)

Pruritus

0

0

1 (20)

0

1 (17)

0

5 (14)

0

1 (17)

0

8 (15)

0

Pneumonia

0

0

0

0

0

0

8 (22)

6 (17)

0

0

8 (15)

6 (11)

Rash

0

0

0

0

1 (17)

0

6 (17)

0

1 (17)

0

8 (15)

0

Abdominal pain

0

0

0

0

0

0

6 (17)

1 (3)

1 (17)

0

7 (13)

1 (2)

Dehydration

0

0

1 (20)

0

2 (33)

1 (17)

4 (11)

2 (6)

0

0

7 (13)

3 (6)

Dry skin

0

0

1 (20)

0

2 (33)

0

4 (11)

0

0

0

7 (13)

0

Hypoalbuminemia

0

0

0

0

3 (50)

0

4 (11)

0

0

0

7 (13)

0

Peripheral edema

0

0

1 (20)

0

1 (17)

0

4 (11)

0

1 (17)

0

7 (13)

0

Weight decreased

0

0

1 (20)

0

2 (33)

0

4 (11)

0

0

0

7 (13)

0

Pleural effusion

0

0

1 (20)

1 (20)

0

0

4 (11)

1 (3)

1 (17)

1 (17)

6 (11)

3 (6)

Muscular weakness

0

0

1 (20)

0

1 (17)

0

2 (6)

0

2 (33)

0

6 (11)

0

  1. ALP alkaline phosphatase, AST aspartate aminotransferase, Q2W once every two weeks, QW once weekly, RDE recommended dose for expansion